Baidu
map

呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

Redx Pharma宣布新的肺纤维化候选药物RXC006

2018-11-15 MedSci MedSci原创

肺纤维化RedxpharmaRXC006
关注

专注于癌症和纤维化的药物发现和开发的Redx公司近日宣布，其首个用于治疗纤维化的口服porcupine抑制剂RXC006将作为孤儿药物用于治疗特发性肺纤维化（IPF）。

专注于癌症和纤维化的药物发现和开发的Redx公司近日宣布，其首个用于治疗纤维化的口服porcupine抑制剂RXC006将作为孤儿药物用于治疗特发性肺纤维化（IPF）。IPF是一种严重且危及生命的慢性肺病，预后极差，且治疗选择有限，患者肺间质的广泛纤维化形成而肺组织增厚，造成不可逆转地丧失肺组织氧气交换的能力，最常发生在50至70岁的老年人。IPF患者的中位生存期仅为3年，美国的年发病率为6.8-16.3 / 100,000。

RXC006是一种通过靶向porcupine（Wnt途径的组分酶）来治疗这种使人衰弱和进行性疾病的新方法。强有力的科学证据表明，该途径与肺部瘢痕形成过程（纤维化）密切相关，这是IPF的标志。随着时间的推移，纤维化导致肺部无法有效发挥作用，最终导致患者窒息死亡。Porcupine抑制剂能够抑制所有Wnt配体的释放，因此能够消除IPF中纤维化的主要驱动因素。临床前测试表明，RXC006在肺部以及肝脏和肾脏中抑制Wnt通路，因此非常有效。


原始出处：

http://www.firstwordpharma.com/node/1604627#axzz5WvWo4v35

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787544, encodeId=d4571e87544b7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue May 21 10:22:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908480, encodeId=00991908480a4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 31 21:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052408, encodeId=1b472052408d5, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Jul 20 05:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793522, encodeId=070e1e9352210, content=<a href='/topic/show?id=d56015e6811' target=_blank style='color:#2F92EE;'>#RXC006#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15768, encryptionId=d56015e6811, topicName=RXC006)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Jun 16 12:22:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-05-21 jj000001

    #Pharm#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1787544, encodeId=d4571e87544b7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue May 21 10:22:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908480, encodeId=00991908480a4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 31 21:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052408, encodeId=1b472052408d5, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Jul 20 05:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793522, encodeId=070e1e9352210, content=<a href='/topic/show?id=d56015e6811' target=_blank style='color:#2F92EE;'>#RXC006#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15768, encryptionId=d56015e6811, topicName=RXC006)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Jun 16 12:22:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-10-31 chentianping

    #pharma#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1787544, encodeId=d4571e87544b7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue May 21 10:22:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908480, encodeId=00991908480a4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 31 21:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052408, encodeId=1b472052408d5, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Jul 20 05:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793522, encodeId=070e1e9352210, content=<a href='/topic/show?id=d56015e6811' target=_blank style='color:#2F92EE;'>#RXC006#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15768, encryptionId=d56015e6811, topicName=RXC006)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Jun 16 12:22:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-07-20 yuanming7

    #候选药物#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1787544, encodeId=d4571e87544b7, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue May 21 10:22:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908480, encodeId=00991908480a4, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Oct 31 21:22:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052408, encodeId=1b472052408d5, content=<a href='/topic/show?id=688a2e469f0' target=_blank style='color:#2F92EE;'>#候选药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27469, encryptionId=688a2e469f0, topicName=候选药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sat Jul 20 05:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793522, encodeId=070e1e9352210, content=<a href='/topic/show?id=d56015e6811' target=_blank style='color:#2F92EE;'>#RXC006#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15768, encryptionId=d56015e6811, topicName=RXC006)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Sun Jun 16 12:22:00 CST 2019, time=2019-06-16, status=1, ipAttribution=)]
    2019-06-16 jianjun66

    #RXC006#

    0

相关资讯

Cell Death Dis：上皮细胞衍生的细胞因子CST3和GDF15可作为肺纤维化的潜在治疗剂

当伤口愈合完成时，上皮细胞通过消除基质重建期间激发的成纤维细胞来使间质环境标准化。否则，组织会发生病理性纤维化。肺纤维化是一种致命的，难以治愈的疾病。我们在此尝试鉴定能够改善肺纤维化的上皮衍生细胞因子。人肺成纤维细胞在上皮细胞条件培养基中失活。胱抑素C（CST3）和生长分化因子15（GDF15）在条件培养基中富集并通过失活TGF-Smad通路来抑制肺成纤维细胞的生长和活化。具有间质纤维化的小鼠和人

Thorax：等待肺移植患者的结局

英国供体肺分配的方式导致了风险概况与肺移植概率之间存在差异。

Inflammation：IL-33因子通过诱导MMP-9和TIMP-1水平的失衡，促进肺纤维化

IL-33可以通过诱导MMP-9和TIMP-1之间的失衡来促进ECM的沉积，促进肺纤维化的过程。 原始出处

Lancet Respir Med：肺纤维化诊断全新方法

本文基于对Fleischner学会成员的医学文献和专家意见所作的系统性研究，提供了一种诊断特发性肺纤维化（IPF）的最新方法，为疑似普通性间质性肺炎（UIP）患者的临床评估提供了标准。

Nat Med：”神药“二甲双胍竟能逆转肺纤维化？

提到二甲双胍(metformin)，人们最先想到的是它是治疗2型糖尿病的药物。确实，二甲双胍是治疗2型糖尿病的一线药物，通常2型糖尿病患者最先服用的药物就是它。但今日在《Nature Medicine》上发表的一项科学研究表明它还有让人意想不到的功用，美国阿拉巴马大学伯明翰分校(University of Alabama at Birmingham， UAB)的研究人员发现它可以逆转已经产生的肺纤

以衰老细胞为靶标的纳米载体药物递送系统

以衰老细胞为靶标的纳米载体药物递送系统正在成为国际医学研究的热点。受损细胞-通常称为僵尸细胞-不能发挥其正常作用，但仍然存活。靶向此类细胞是一项关键挑战，因为它们会干扰组织的功能并导致与衰老相关的持续性恶化。西班牙的细胞可塑性和疾病实验室的科学家Manuel Serrano博士开发了专门针对衰老细胞的药物传递系统。

Baidu
map
Baidu
map
Baidu
map